Trouble sleeping? These are the 7 products our editors swear by for a good night's sleep

After our fair share of restless nights, mattress testing, bedding shopping and sleep tech reviewing, we're confident we know what it takes to get a good night's sleep. Optimizing our sleep is part of our day job, after all.
As well as sleeping on and testing the best mattresses of the year, there are a handful of products our writers and editors simply can't sleep without. From the humble ear plugs and socks to more technical products, like sleep trackers and sleep headbands, this is a list of the gear the Tom's Guide Sleep Team rely on for a good night's sleep.
SPONSORED
Sealy Posturepedic Elite Hybrid : Getting the sleep you need improves a litany of issues, but you can't get that sleep if you're waking up stiff and sore. The targeted support of a Sealy Posturepedic® Elite Hybrid mattress helps provide relief where you need it most. This bed flexes to your unique shape, making sure you find the personalized support you need to perform your best in the morning.
7 products our editors swear by for better sleep
We'll be honest, not all the products we test perform as well as their makers promise they do. But these aren't the products we're focusing on here. Instead, you'll find our favorite, trusty gadgets that have actually sent us to sleep fast and keep us snoozing all night long...
1. Loop Dream Earplugs: $49.95 at Loop Earplugs
Be it a busy street outside your bedroom window, noisy neighbours or a snoring partner, noise pollution is a common sleep disruptor. But with the Loop Dream Earplugs, our Sleep Editor Nicola Appleton sleeps soundly. She says: 'After 14 years of sleeping next to someone who snores, I tried the Loop Dream Earplugs — the first sleep-specific option from Loop — and haven't looked back. With a noise reduction rating of 27dB (SNR), they block out my partner's snoring completely — which means I can finally get an undisturbed night's rest. With their ultra-soft silicone and a flat, closed-loop design, they're also ideal for side sleepers like me. And, with four ear tip sizes, they stay securely in place all night. If someone else's snoring is keeping you awake, these ear plugs will save your sleep.'
2. Samsung Galaxy Ring: $399.99 at Samsung
While we're aware sleep trackers don't directly improve your sleep, we use them to learn more about our sleep patterns and tendencies. Our Sleep Features Editor Lauren Jeffries has been testing the Samsung Galaxy ring. Here's what she has to say about it's sleep tracking functionality: "I've never used any kind of sleep tracker before the Galaxy Ring. Yes, I had nightmares and probably didn't get enough sleep most nights, but in general, I felt well rested. The Galaxy Ring has educated me so much that I'm now getting better sleep every night. This is mainly because of the sleep score. I love how detailed it is, looking at every aspect that went into calculating it, from sleep duration and my bedtime, to the amount of REM sleep I got and how long it took me to fall asleep. Since using it, my sleep schedule has become more consistent and I prioritize getting quality rest over quantity, which has also helped my nighttime anxiety."
3. Women's Fine Cashmere and Merino Wool Super Soft Socks: $29.99 at Amazon
Wearing socks to bed is a disputed topic on our sleep team. While some say it makes them feel claustrophobic, others enjoy their sleep-enhancing benefits, and science suggests the latter group are right. Nicola says: 'Wearing socks to bed is a simple, science-backed habit with a big payoff — falling asleep faster and staying asleep longer. Instead of making you hot, socks gently warm your feet, triggering vasodilation, which actually helps lower your core temperature — a critical cue for falling asleep. Cold feet, on the other hand, can delay sleep onset and lead to restless tossing and turning. In the warmer summer months always opt for a lightweight, breathable fabric like cotton or cashmere.' This pair from Amazon are reasonably priced and come in 14 color options.
4. Philips SmartSleep Sleep and Wake-Up Light: $213.22 at Amazon
A top sunrise alarm clock is a staple on my bedside table now, no matter the season. As a sleep tech writer, my current favorite is the Philips SmartSleep Wake-Up Light. In winter, it helps me wake up to light. Even though the mornings are naturally light now, I still enjoys using the sunset simulation as part of my wind down routine. Plus the gentle wake up sounds are much better than a jolting iPhone alarm. The Philips is a more expensive sunrise alarm clock option, but functioning as a bedside reading lamp too, I think it's worth the splurge.
5. Elemind sleep headband: $349 at Elemind
The Elemind headband is part of the emerging sleep headband market. Placed over your forehead, the headband measures EEG brain signals and delivers precise acoustic stimulation that moves the brain from wakeful patterns into a deeper sleep. I have been using this headband to get more deep sleep while marathon training. I've slept all night long wearing it and can vouch for its efficiency considering I stayed asleep even when my brother came into my bedroom to steal an iPhone charger plugged in next to my bed (though he was slightly confused by my sleep accessory). At $349, this is a premium sleep product, which will only be worth it if you're really struggling to switch off at night.
6. Feather & Down Sweet Dream Pillow Spray: $17 at Amazon
Essential oils like lavender and chamomile are known to calm the nervous system, promoting overall relaxation. Our Senior Sleep Writer, Frances Daniels, uses the Feather & Down Sweet Dream Pillow Spray to make the most of this relaxation technique. She says: "Spritzing my bedding with lavender pillow spray has become a comforting bedtime ritual for me, and helps me to fall asleep faster. It may just be a placebo effect, but studieshave shown that the soothing scent can increase sleep quality and ease anxiety." At just $17, this is an affordable sleep product.
7. MZOO Sleep Eye Mask: was $28.99 now $22.99 at Amazon
Light is a major sleep killer for our Senior Sleep Writer, Ruth Jones, so she relies on a comfy eye mask to create the perfect environment for rest, whether she's on her friend's sofa or a cross-Atlantic airline. She says: "My eye mask blocks the lights that plague my bedroom — like the smoke detector and power strip — and it also helps me put my phone away at night. After all, once my eye mask is on, I can't check my messages any more. Just the action of putting an eye mask on has come to signal to my brain that it's time to go to sleep and I find it's weight on my face strangely comforting now." The MZOO is a great value, great quality sleep mask option with 21% off at Amazon now, bringing the price to $22.99. Yes it's a bit more than your average silk mask, but made with soft fabric, it'll be more durable.
Sign up to get the BEST of Tom's Guide direct to your inbox.
Get instant access to breaking news, the hottest reviews, great deals and helpful tips. Contact me with news and offers from other Future brands Receive email from us on behalf of our trusted partners or sponsors

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Upturn

2 days ago

• Business Upturn

Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA

By GlobeNewswire Published on June 21, 2025, 04:38 IST Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA Results from the phase 3b STEP UP trial showed that a higher dose of Wegovy ® (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo 1 (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo Safety and tolerability of the higher dose of Wegovy ® (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg) 1 (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg) The STEP UP data add to the existing evidence base on the value of Wegovy® in delivering significant weight loss and health gains for people living with obesity Bagsværd, Denmark, 21 June 2025 – Novo Nordisk today presented the results from the phase 3b STEP UP trial in people with obesity without diabetes at the American Diabetes Association (ADA) Scientific Sessions, in Chicago, US. In the STEP UP trial, the higher dose of Wegovy® (semaglutide 7.2 mg) demonstrated a mean weight loss of 21%, with a third of participants losing 25% or more of their body weight compared to placebo at 72 weeks.1 'The STEP UP trial demonstrated that we can increase the dose of semaglutide and achieve greater weight loss than previously seen, and in line with semaglutide's established safety profile. This may offer another option to people who do not attain their weight goals,' said Sean Wharton, lead study author and medical director of the Wharton Medical Clinic, Canada. 'We are already aware that semaglutide can have health benefits for people with heart disease, liver disease, knee osteoarthritis, type 2 diabetes and prediabetes. These findings help to give patients with obesity more options for improvements in their weight and overall health.' STEP UP co-primary endpoints at 72 weeks *1 : semaglutide 7.2 mg semaglutide 2.4 mg PlaceboWeight loss 20.7% 17.5% 2.4% 5% or more weight loss 93.2% 92.5% 35.7% When evaluating the effect of treatment regardless of treatment adherence, people receiving semaglutide 7.2 mg achieved 18.7% weight loss vs 3.9% with placebo, and 90.7% achieved 5% or more weight loss with semaglutide 7.2 mg vs 36.8% on placebo. 'With these results, semaglutide reaffirms its significant weight loss for people with obesity. The STEP UP trial delivers a substantial weight loss of over 20%, in addition to health benefits previously demonstrated with semaglutide,' said Ludovic Helfgott, executive vice president of Product & Portfolio Strategy at Novo Nordisk. 'As pioneers in obesity, we continue to develop new innovative treatments to fit the needs and preferences of people living with obesity. This includes maximising the value of semaglutide for individuals, healthcare systems and society, and developing a new oral formulation of Wegovy® that, pending FDA approval, can become the first GLP-1 pill to offer double-digit weight loss.' In the STEP UP trial, semaglutide 7.2 mg demonstrated a well-tolerated safety profile consistent with previous Novo Nordisk semaglutide trials.1 The most common adverse events were gastrointestinal, and the vast majority were mild to moderate during dose escalation and diminished over time, consistent with the GLP-1 class.1 In STEP UP, 3.3% of people treated with semaglutide 7.2 mg discontinued due to gastrointestinal adverse events, compared to 2.0% with semaglutide 2.4 mg and 0% with placebo.1 Novo Nordisk expects to file the higher dose of Wegovy® for a label update in the EU in the second half of 2025, followed by regulatory submissions in other markets where Wegovy® is already approved. STEP UP selected confirmatory secondary endpoints at 72 weeks * 1 : semaglutide 7.2 mg semaglutide 2.4 mg Placebo10% or more weight loss 86.0% 77.6% 20.0%15% or more weight loss 70.4% 57.5% 7.9%20% or more weight loss 50.9% 35.1% 2.9% 25% or more weight loss 33.2% 16.7% 0% * Based on the trial product estimand: treatment effect if all people adhered to treatment. About the STEP UP trials Novo Nordisk has completed two trials, STEP UP and STEP UP T2D, investigating the efficacy and safety of semaglutide 7.2 mg in people with obesity with or without type 2 diabetes. The 72-week STEP UP trial was a randomised, double-blinded, parallel-group, placebo-controlled, superiority trial designed to evaluate the efficacy and safety of semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo as an adjunct to lifestyle intervention. The trial included 1,407 adults with a BMI ≥30 kg/m2 without diabetes. The primary objective was to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. Key confirmatory secondary endpoints included the number of participants achieving 10%, 15%, 20% and 25% weight loss, respectively. The 72-week STEP UP T2D trial investigated semaglutide 7.2 mg in 512 adults with obesity and type 2 diabetes, with the primary objective to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. About Wegovy® Semaglutide 2.4 mg is marketed under the brand name Wegovy®. In the EU, Wegovy® is indicated as an adjunct to a reduced calorie diet and increased physical activity for weight management in adults with a BMI of 30 kg/m2 or greater (obesity) or adults with a BMI of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. In the EU, Wegovy® is also indicated for paediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and gender (obesity) and body weight above 60 kg. The clinical section of the label also includes data on Wegovy® major adverse cardiovascular events (MACE) risk reduction, improvements in HFpEF-related symptoms and physical function, as well as pain reduction related to knee osteoarthritis. In the US, Wegovy® is indicated in combination with a reduced calorie diet and increased physical activity to reduce the risk of MACE in adults with established cardiovascular disease and either obesity or overweight, as well as to reduce excess body weight and maintain weight reduction long term in paediatric patients aged 12 years and older with obesity and in adults with obesity or with overweight in the presence of at least one weight-related comorbid condition. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit , Facebook , Instagram , X , LinkedIn and YouTube . Contacts for further information References Wharton, S, et al. (2025). Once-weekly semaglutide 7.2 mg in adults with obesity: the randomised, controlled, phase 3b STEP UP trial. 1966-LB poster. American Diabetes Association (ADA) 85th Scientific Sessions, Chicago, US, June 20 – 23, 2025.17. Attachment Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.

Yahoo

2 days ago

• Yahoo

argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy

VYVGART® SC, first-and-only IgG Fc-antibody fragment which specifically targets the neonatal Fc receptor (FcRn), now approved for use in Europe for CIDP Approval based on ADHERE clinical trial, the largest study of CIDP patients to date First novel mechanism of action for CIDP treatment in more than 30 years June 20, 2025, 7:00 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the European Commission (EC) approved VYVGART® (efgartigimod alfa) 1000mg for subcutaneous (SC) injection as a monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment with corticosteroids or immunoglobulins. VYVGART for SC injection is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional. Treatment is initiated with a weekly dose regimen and may be adjusted to every other week based on clinical evaluation. "The EC's decision has been met with hope and enthusiasm by the European Patient Organisation for Dysimmune and Inflammatory Neuropathies (EPODIN). We see the introduction of a new targeted therapy for CIDP as a major step forward for the patient community," said Jean-Philippe Plançon, President of EPODIN. CIDP is a rare, debilitating, often progressive, immune-mediated neuromuscular disorder of the peripheral nervous system. Patients experience a range of disabling mobility and sensory issues, including trouble standing from a seated position, pain and fatigue, and frequent tripping or falling. People living with CIDP can also become wheelchair bound and unable to work as the disease progresses. Currently, 85% of patients require ongoing treatment and nearly 88% of treated patients experience residual impairment and disability. 'CIDP can severely affect quality of life by causing weakness, loss of balance and mobility, numbness and pain in a patient's arms and legs. For far too long, physicians have had limited options for helping to improve patient outcomes,' said Dr. Luis Querol, M.D., Ph.D., ADHERE Investigator, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. 'The approval of VYVGART SC for the treatment of CIDP marks a turning point in clinical practice, as physicians now have access to a new, effective treatment option that, for the first time, precisely targets a key mechanism of disease and provides meaningful functional improvements to patients.' The EC approval follows a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) and is based on positive results from the ADHERE clinical trial, the largest study of CIDP patients to date. In the study, 66.5% (214/322) of patients treated with VYVGART SC demonstrated evidence of clinical improvement, including in mobility, function and strength. Clinical benefit was seen across all patient subtypes, regardless of prior treatment. ADHERE met its primary endpoint (p<0.0001) demonstrating a 61% reduction (HR: 0.39 95% CI: 0.25; 0.61) in the risk of relapse versus placebo. 99% of trial participants elected to participate in the ADHERE open-label extension. The safety results were consistent with the known safety profile of VYVGART SC in previous clinical studies. 'VYVGART SC is the first therapy with a novel mechanism of action to be approved for this community in more than 30 years,' said Luc Truyen, M.D., Ph.D., Chief Medical Officer of argenx. 'With VYVGART SC, CIDP patients and physicians across Europe will soon have access to an effective novel therapy with a favorable safety profile that has a precise mechanism of action and a convenient self-injection option. This approval further affirms the potential of efgartigimod in IgG-mediated autoimmune diseases.' The EC approval will apply to all 27 European Union Member States, and also to Iceland, Liechtenstein, and Norway. argenx is working closely with local regulatory authorities across the region to ensure that patients who may benefit from VYVGART SC are able to access the novel treatment as soon as possible. This regulatory approval is the second for VYVGART SC in Europe, which first received approval as an add-on to standard therapy for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. About ADHERE The ADHERE trial was a multi-center, randomised, double-blind, placebo-controlled trial evaluating efgartigimod alfa SC for the treatment of CIDP. ADHERE enrolled 322 adult patients with CIDP, 130 of whom were based in Europe. The trial consisted of an open-label Stage A followed by a randomized, placebo-controlled Stage B. In order to be eligible for the trial, the diagnosis of CIDP was confirmed by an independent panel of experts. Patients entered a run-in stage, where any ongoing CIDP treatment was stopped and, in order to be eligible for Stage A, had to demonstrate active disease with clinically meaningful worsening on at least one CIDP clinical assessment tool, including INCAT, I-RODS, or mean grip strength. Treatment-naïve patients were able to skip the run-in period with proof of recent worsening. To advance to Stage B, patients needed to demonstrate evidence of clinical improvement (ECI) with efgartigimod alfa SC. ECI was achieved through improvement of the INCAT score, or improvement on I- RODS or mean grip strength if those scales had demonstrated worsening during the run-in period. In Stage B, patients were randomized to either efgartigimod alfa SC or placebo for up to 48 weeks. The primary endpoint was measured once 88 total relapses or events were achieved in Stage B and was based on the hazard ratio for the time to first adjusted INCAT deterioration (i.e. relapse). After Stage B, all patients had the option to roll-over to an open-label extension study to receive efgartigimod alfa SC. About Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)CIDP is a rare and serious autoimmune disease of the peripheral nervous system. There is increasing evidence that IgG antibodies play a key role in the damage to the peripheral nerves. People with CIDP experience fatigue, muscle weakness and a loss of feeling in their arms and legs that can worsen over time or may come and go. These symptoms can significantly impair a person's ability to function in their daily lives. Without treatment, one-third of people living with CIDP will need a wheelchair. About Efgartigimod SCEfgartigimod SC (efgartigimod alfa) is a human IgG1 antibody fragment designed to reduce pathogenic immunoglobulin G (IgG) antibodies by binding to the neonatal Fc receptor (FcRn) and blocking the IgG recycling process. Efgartigimod SC is the first-approved FcRn blocker globally and is marketed as VYVGART® Hytrulo in the United States and China for the treatment of generalized myasthenia gravis (gMG) and CIDP; as VYVDURA in Japan for gMG and CIDP; and as VYVGART for gMG and CIDP in other regions globally. Efgartigimod SC is currently being evaluated in more than 15 severe autoimmune diseases where pathogenic IgGs are believed to be mediators of disease. About argenxargenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercialising the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit and follow us on LinkedIn, Instagram, Facebook, and YouTube. Contacts Media:Kate Dion kdion@ Investors: Alexandra Royaroy@ Forward-Looking Statements The contents of this announcement include statements that are, or may be deemed to be, 'forward-looking statements.' These forward-looking statements can be identified by the use of forward-looking terminology, including the terms 'aim,' 'is,' 'can,' 'may,' 'will,' and 'believe' and include statements argenx makes concerning argenx's aim to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines; its belief that the approval of VYVGART SC for the treatment of CIDP may bring meaningful functional improvements to patients; the timing of access to an effective novel therapy for CIDP patients and physicians across Europe; and the potential of efgartigimod in IgG-mediated autoimmune diseases. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx's actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including but not limited to, the results of argenx's clinical trials; expectations regarding the inherent uncertainties associated with the development of novel drug therapies; preclinical and clinical trial and product development activities and regulatory approval requirements; the acceptance of its products and product candidates by its patients as safe, effective and cost-effective; the impact of governmental laws and regulations, including tariffs, export controls, sanctions and other regulations on its business; its reliance on third-party suppliers, service providers and manufacturers; inflation and deflation and the corresponding fluctuations in interest rates; and regional instability and conflicts. A further list and description of these risks, uncertainties and other risks can be found in argenx's U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx's most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Business Wire

3 days ago

• Business Wire

Mirion Medical to Debut New Solutions, Highlight Broad Radiopharma-Focused Portfolio at SNMMI Annual Meeting

ATLANTA--(BUSINESS WIRE)-- Mirion, a global leader in radiation safety, science, and medicine, announced today that its Mirion Medical group will showcase its portfolio of solutions designed to enable the radiopharma and theranostic fields at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, June 21-24, in New Orleans, Louisiana. New products from Capintec and Dosimetry Services will be introduced alongside innovations from the broader Mirion portfolio, including the ec 2 Software suite and advances from Mirion Technologies. Debuting at the 2025 SNMMI Annual Meeting Graves Phantom from Capintec, a Mirion Medical company: The Graves Phantom is a groundbreaking, solution for enabling precise dosimetry in radiopharmaceutical therapy (RPT). Designed as a 20-cm tissue-equivalent phantom, it supports the calibration of SPECT systems per radioisotope and allows for accurate sensitivity factor measurements under realistic scatter conditions, enabling reliable and reproducible RPT workflows. Instadose ® VUE Beta Dosimeter from Dosimetry Services, a Mirion Medical company: The only hybrid wireless dosimeter designed for theranostic applications, the InstadoseVUE Beta device tracks and measures radiation exposure, ensuring the safety of medical staff in environments where beta radiation is present. The InstadoseVUE Beta is the latest model in the InstadoseVUE line of wireless dosimeters for radiation monitoring of personnel. Additional Featured Solutions from the Broader Mirion Portfolio ec 2 Software Suite: ec 2 Software, a Mirion Medical company, provides software to simplify workflows, support regulatory compliance, and drive operational efficiency for stakeholders across the nuclear medicine, molecular imaging and radiopharmaceutical fields​​. Demonstrations for applications including BioTrax™ QMS, NMIS™, and BioRx™ will be available throughout the SNMMI Annual Meeting. Apex-Guard™ Software: From Mirion Technologies, the newest version of Apex-Guard software includes a robust impurity analysis feature and patent-pending algorithm for gamma spectroscopy measurements, which simplifies radioisotope production quality management, boosts confidence in radioisotope safety, and aids in regulatory compliance. The software integrates with BioTrax QMS, improving workflow efficiency and data integrity. Portable and Mobile Radiation Monitoring: New solutions from Mirion Technologies include the CSPevo ® Probe and RDS-Med™ Survey Meter for comprehensive, portable radiation survey monitoring and the IC3™ Portable Ion Chamber Survey Meter for measuring gamma, beta and X-ray radiation. In addition, the iCAM™ Mobile Alpha/Beta Particulate Monitor for reliable monitoring of airborne activity will be on hand. 'As the nuclear medicine and molecular imaging landscape evolves, Mirion is committed to leveraging our deep expertise in ionizing radiation to serve our customers and ensure safe, efficient operations at every step,' said Luis Rivera, Executive Vice President of Mirion Medical. 'From research to production to patient care, Mirion Medical and Mirion Technologies alike are developing solutions to drive higher quality. We look forward to demonstrating how these solutions can shape a more connected future.' Commitment to Patient Care and Safety Mirion Medical is a proud sponsor of the SNMMI 2025 Patient Education Day, contributing educational resources and insights on radiation safety. This sponsorship reflects Mirion's commitment to patient education and awareness, ensuring that patients and their families are well-informed about the benefits of nuclear medicine and molecular imaging. About Mirion Mirion is a global leader in radiation safety, science and medicine, empowering innovations that deliver vital protection while harnessing the transformative potential of ionizing radiation across a diversity of end markets. The Mirion Technologies group is committed to powering advancements in nuclear energy through proven radiation safety technologies and expertise. The Mirion Medical group is focused on improving quality in cancer care through its broad range of solutions that enhance delivery and ensure safety across the medical landscape. Headquartered in Atlanta (GA – USA), Mirion employs approximately 2,800 people and operates in 12 countries. ©2025 Mirion. All rights reserved. Instadose®VUE, BioTrax™ QMS, NMIS™, BioRx™, CSPevo™, Apex-Guard™, IC3™, and iCAM™ are trademarks or registered trademarks of Mirion Technologies, Inc. and/or its affiliates in the United States and/or other countries.